These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
198 related items for PubMed ID: 25034323
1. Does dabigatran interfere with intraablation heparinization? Sairaku A, Nakano Y, Kihara Y. Thromb Res; 2014 Sep; 134(3):742-3. PubMed ID: 25034323 [No Abstract] [Full Text] [Related]
2. Dabigatran use in elderly patients with atrial fibrillation. Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, Pilote L. Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766 [Abstract] [Full Text] [Related]
3. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Lee KH, Park HW, Lee N, Hyun DY, Won J, Oh SS, Park HJ, Kim Y, Cho JY, Kim MC, Sim DS, Yoon HJ, Yoon NS, Kim KH, Hong YJ, Kim JH, Ahn Y, Jeong MH, Park JC, Cho JG. Europace; 2017 Dec 01; 19(suppl_4):iv1-iv9. PubMed ID: 29220421 [Abstract] [Full Text] [Related]
4. Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment. Zhang RF, Ma CM, Wang N, Yang MH, Li WW, Yin XM, Dong YX, Yu XH, Xiao XJ, Xia YL, Gao LJ. BMC Cardiovasc Disord; 2021 Apr 27; 21(1):214. PubMed ID: 33906609 [Abstract] [Full Text] [Related]
5. Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran. Stabile E, Izzo R, Rozza F, Losi MA, Coscioni E, Trimarco B. High Blood Press Cardiovasc Prev; 2016 Jun 27; 23(2):115-22. PubMed ID: 27207360 [Abstract] [Full Text] [Related]
6. Meta-analysis of dabigatran vs warfarin in patients undergoing catheter ablation for atrial fibrillation. Phan K, Wang N, Pison L, Kumar N, Hitos K, Thomas SP. Int J Cardiol; 2015 Jun 15; 189():199-203. PubMed ID: 25897906 [No Abstract] [Full Text] [Related]
7. Which oral anticoagulant for atrial fibrillation. Med Lett Drugs Ther; 2016 Apr 11; 58(1492):45-6. PubMed ID: 27049507 [No Abstract] [Full Text] [Related]
8. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S. J Cardiovasc Electrophysiol; 2019 Dec 11; 30(12):2823-2833. PubMed ID: 31701593 [Abstract] [Full Text] [Related]
9. Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study. Calkins H, Willems S, Verma A, Schilling R, Hohnloser SH, Okumura K, Nordaby M, Kleine E, Bis B, Gerstenfeld EP. Europace; 2019 Jun 01; 21(6):879-885. PubMed ID: 30982849 [Abstract] [Full Text] [Related]
10. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, Koplan BA, McClennen S, Michaud GF. J Cardiovasc Electrophysiol; 2011 Mar 01; 22(3):248-54. PubMed ID: 20812929 [Abstract] [Full Text] [Related]
11. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Europace; 2018 Feb 01; 20(2):253-262. PubMed ID: 28520924 [Abstract] [Full Text] [Related]
12. RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures. Camm AJ. Cardiovasc Res; 2018 Oct 01; 114(12):e89-e90. PubMed ID: 31346598 [No Abstract] [Full Text] [Related]
13. Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Essebag V, Proietti R, Birnie DH, Wang J, Douketis J, Coutu B, Parkash R, Lip GYH, Hohnloser SH, Moriarty A, Oldgren J, Connolly SJ, Ezekowitz M, Healey JS. Europace; 2017 Oct 01; 19(10):1630-1636. PubMed ID: 28339794 [Abstract] [Full Text] [Related]
14. Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block. Pelargonio G, Perna F. J Cardiovasc Electrophysiol; 2013 Aug 01; 24(8):866-8. PubMed ID: 23647979 [No Abstract] [Full Text] [Related]
15. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S. J Cardiovasc Electrophysiol; 2018 Jun 01; 29(6):835-843. PubMed ID: 29533476 [Abstract] [Full Text] [Related]
16. [Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice]. Tkacheva ON, Akasheva DU. Ter Arkh; 2014 Jun 01; 86(4):103-7. PubMed ID: 24864477 [Abstract] [Full Text] [Related]
17. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP. J Interv Card Electrophysiol; 2012 Dec 01; 35(3):277-84; discussion 284. PubMed ID: 23015216 [Abstract] [Full Text] [Related]
18. A comparison of bleeding complications post-ablation between warfarin and dabigatran. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F. J Interv Card Electrophysiol; 2012 Oct 01; 35(1):29-33. PubMed ID: 22869389 [Abstract] [Full Text] [Related]
19. Influence of the concomitant use of heparin on the effects of warfarin during catheter ablation for atrial fibrillation. Inada K, Matsuo S, Tokutake K, Yokoyama K, Hioki M, Narui R, Ito K, Tanigawa S, Yamashita S, Tokuda M, Shibayama K, Miyanaga S, Sugimoto K, Yoshimura M, Yamane T. Heart Vessels; 2016 Mar 01; 31(3):397-401. PubMed ID: 25471944 [Abstract] [Full Text] [Related]
20. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. Steg PG, Ducrocq G, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. J Am Coll Cardiol; 2020 Jan 21; 75(2):238-240. PubMed ID: 31948654 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]